scio-469 and Acute-Pain

scio-469 has been researched along with Acute-Pain* in 1 studies

Trials

1 trial(s) available for scio-469 and Acute-Pain

ArticleYear
Novel p38α mitogen-activated protein kinase inhibitor shows analgesic efficacy in acute postsurgical dental pain.
    Journal of clinical pharmacology, 2012, Volume: 52, Issue:5

    SCIO-469 is a selective p38α mitogen-activated protein kinase (MAPK) inhibitor for preclinical models of acute pain. This prospective, double-blind, randomized clinical study compared efficacy and safety of oral SCIO-469, ibuprofen, and placebo in postsurgical dental pain. Subjects (n = 263) undergoing extraction of 1 or more impacted mandibular third molars received preoperative treatment with SCIO-469 (150, 210, or 300 mg), ibuprofen (400 mg), or placebo; the 210-mg group received 90 mg postoperatively. A 4-point categorical scale and a 100-mm visual analogue scale were used to measure pain intensity. The primary end point was median time from first incision to first rescue medication using the Kaplan-Meier product limit estimator. All SCIO-469 groups had significantly longer times to rescue medication compared with placebo; preoperative and postoperative treatment with 210 + 90 mg SCIO-469 resulted in 8.1 hours versus 4.1 hours to rescue for placebo (P = .003). Ibuprofen also increased time to rescue medication (6.6 hours) versus placebo (P = .04). Dizziness, headache, and nausea were the most frequently reported adverse events. This is the first clinical demonstration of antinociceptive effects in acute pain with preoperative administration of a p38α MAPK inhibitor.

    Topics: Acute Pain; Administration, Oral; Adolescent; Adult; Analgesics; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibuprofen; Indoles; Kaplan-Meier Estimate; Male; Mitogen-Activated Protein Kinase 14; Molar, Third; Pain Measurement; Prospective Studies; Protein Kinase Inhibitors; Time Factors; Tooth Extraction; Tooth, Impacted; Treatment Outcome; United States; Young Adult

2012